OYSTER POINT PHARMA, INC. (OYST): Price and Financial Metrics
OYST Price/Volume Stats
| Current price | $11.17 | 52-week high | $19.00 |
| Prev. close | $11.15 | 52-week low | $3.46 |
| Day low | $11.12 | Volume | 2,088,200 |
| Day high | $11.20 | Avg. volume | 212,171 |
| 50-day MA | $10.42 | Dividend yield | N/A |
| 200-day MA | $7.48 | Market Cap | 299.85M |
OYST Stock Price Chart Interactive Chart >
OYSTER POINT PHARMA, INC. (OYST) Company Bio
Oyster Point Pharma, Inc. engages in the development and commercialization of pharmaceutical therapies to treat ocular surface diseases. Its lead product candidate, OC-01, is a nicotinic acetylcholine receptor agonist, which is being developed as a nasal spray to treat the signs and symptoms of dry eye disease. The company was founded by Michael and is Ackermann in June 30, 2015 headquartered in Princeton, NJ.
Latest OYST News From Around the Web
Below are the latest news stories about OYSTER POINT PHARMA INC that investors may wish to consider to help them evaluate OYST as an investment opportunity.
Viatris completes 2 key acquisitions in vision careThe two companies will be combined into a vision-care division of the Canonsburg pharmaceutical company. |
The 7 Best Crypto and Stocks to Buy as Christmas Gifts This YearThese stocks to buy as Christmas gifts provide a number of reasons for investors to rejoice this holiday season. |
The 7 Hottest Healthcare Stocks to Own for 2023 and BeyondAs their respective catalysts (namely new treatments/products) continue to play out, each one of these seven hottest healthcare stocks has a strong chance of making another significant move higher in 2023, and in the years ahead. |
Oyster Point Pharma: Interesting Opportunity To Acquire Undervalued CVR (NASDAQ:OYST)Oyster Point Pharma is being acquired by Viatris. Tender offer includes a contingent value right that''s based on full-year 2022 metrics. Read more on OYST here. |
Oyster Point Pharma, Inc., Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)PRINCETON, N.J., Dec. 02, 2022 (GLOBE NEWSWIRE) -- Oyster Point Pharma, Inc., (Nasdaq: OYST), (“Oyster Point Pharma”, or “the Company”), a commercial-stage biopharmaceutical company focused on the discovery, development and commercialization of first-in-class pharmaceutical therapies to treat ophthalmic diseases, today announced that the Compensation Committee of the Company’s Board of Directors granted inducement non-qualified stock options to purchase an aggregate of 11,300 shares of common st |
OYST Price Returns
| 1-mo | N/A |
| 3-mo | N/A |
| 6-mo | N/A |
| 1-year | N/A |
| 3-year | -45.78% |
| 5-year | N/A |
| YTD | N/A |
| 2023 | 0.00% |
| 2022 | -38.83% |
| 2021 | -2.98% |
| 2020 | -23.00% |
| 2019 | N/A |
Loading social stream, please wait...